Neuroscience CRO

Accelerating Clinical Development in Neuroscience for Transformative Therapies

At the forefront of clinical development for neuroscience indications, Lotus has extensive experience across the full spectrum of neurological disorders. Our team is committed to advancing novel therapies through every phase of development. With exceptional scientific leadership, access to top-performing sites, and a comprehensive understanding of the complexities of neuroscience clinical development, we can help streamline your investment in transformative treatments that can change the lives of patients worldwide.

Neuroscience Drug Approvals

0 +

Neuroscience Studies Completed

Number FDA Inspections Resulting in a 483

Note: Statistics combine experience from both Lotus Clinical Research and Evolution Research Group’s network of clinical research sites.

Improving Patients' Lives through Neuroscience Clinical Research

Having run hundreds of trials across the CNS spectrum including psychiatry, pain, neurology, addiction and sleep disorders, Lotus can help streamline and accelerate your next clinical trial. Our Scientific Leadership Team, comprised of industry-recognized MDs, PIs, KOLs, scientists, clinicians, and regulatory and operational experts, apply decades of research and experience to ensure your trial is set up for success.

CNS Drug Approvals

Our experts in Neuroscience clinical development can help you too.

Dive Deeper into our Areas of Expertise as a Neuroscience CRO

Note: Statistics combine experience from both Lotus Clinical Research and Evolution Research Group’s network of clinical research sites

Psychiatry

Over 1800 studies across all major mental health diseases.

Pain

Over 600 studies in acute and chronic pain.

Neurology

Over 1600 studies across all phases of development.

Addiction

Over 70 studies to treat addiction and prevent relapse.

Early Phase Clinical Development

Lotus brings extensive expertise in Phase 1 clinical trials, supporting both healthy volunteers and patient populations across a range of early development studies. Our dedicated Early Development Services (EDS) team specializes in clinical pharmacology studies, including FIH, SAD/MAD, DDI, BE/BA, QTc/TQT, and more, having contributed to nearly 100 SAD/MAD trials. With a strong focus on early signal detection and complex trial designs, we efficiently manage Phase I-IIa studies incorporating biomarkers, neuroimaging, and specialized procedures. Backed by expert project teams and access to top Phase I units, Lotus is a trusted partner in driving early-phase clinical success.

Scientific Leadership Team: Your Advantage for Accelerating Your Clinical Development

Our Scientific Leadership Team’s (SLT) mission is to help Sponsors critically evaluate all aspects of their study, to both streamline its execution and to avoid missteps that may cause expensive delays. Even before we are awarded a study, an in-depth review is conducted to carefully evaluate the feasibility of the study from scientific, operational, and regulatory perspectives. This allows us to provide meaningful, early feedback. While success is never guaranteed in the execution of any clinical trial, our goal is to gather input from all experts, anticipate what challenges we may face, and then minimize the risk to both the trial and to our reputation—including recommending only those sites we feel are well-suited to conduct the research. Once awarded, the SLT stays informed and engaged, constantly guiding and adjusting as the trial progresses.

Work with Quality Sites with Access to Special Patient Populations

The ERG network—including 20 wholly-owned US-based sites—is a market leader in neuroscience clinical studies. A reputation for patient engagement and quality makes them highly sought-after research sites. With the LOTUS-ERG affiliation, your studies will be prioritized and you’ll collaborate with top PIs and KOLs who ensure operational and scientific risks are minimized, and your studies are run efficiently at the best-qualified sites.